Investigation of The Prevalence of Sepsis in Adults in Multicenter Intensive Care Unıts in Turkey

NCT ID: NCT03179189

Last Updated: 2017-09-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-10-01

Study Completion Date

2018-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The pathophysiology and treatment of sepsis disease are still not fully known. International guides often refer to the studies done in the developed countries and suggest some treatments. The infrastructure of the developing countries is quite different. For this reason, it is not exactly scientific how much these proposals are reflected in patient treatment. In our study, We will try to reveal the treatment of sepsis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sepsis is a clinical syndrome that has physiologic, biologic, and biochemical abnormalities caused by a dysregulated inflammatory response to infection. Sepsis and the inflammatory response that ensues can lead to multiple organ dysfunction syndrome and death. In the late 1970s, it was estimated that 164,000 cases of sepsis occurred in the United States (US) each year. Since then, rates of sepsis in the US and elsewhere have dramatically increased as supported by the following studies, although many of these are derived from academic institutions. The increased rate of sepsis is thought to be a consequence of advancing age, immunosuppression, and multidrug-resistant infection. It is also likely to be due to the increased detection of early sepsis from aggressive sepsis education and awareness campaigns, although this hypothesis is unproven. Guidelines should focus on pre-hospital assessment and triage. Indeed, respiratory infections represented the most common cause of sepsis in that cohort, and postoperative infections were another important part of the problem. Whether these conditions apply to patients with shock in low-income and middle-income countries (LMIC) is unknown, but the incidence of community-acquired infections would be higher, with a greater prevalence of gastroenteritis, septic abortion, and skin and soft tissue infections as causes of septic shock. The bacteriology of bloodstream infections across LMICs varies substantially depending on regional and population characteristics. In a meta-analysis of 19 prospective studies on community-acquired bacteraemia in Africa, the most common organisms isolated were Salmonella spp (predominantly non-typhi), Streptococcus pneumoniae, and Gram-negative organisms such as Escherichia coli.11 Among cases for which mortality data were recorded, patients with bloodstream infections had an average mortality of 21.5%. Although data are lacking, appropriate antibiotic treatment for these infections on the basis of bacterial resistance patterns will ultimately depend on the ecological pressures resulting from local antibiotic availability and patterns of use.

We aimed to evaluate the approach to sepsis in Turkey as a multi-centered study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 year old over

Exclusion Criteria

* Non-life expectant Those who live longer than 24 hours not that consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Izmir Ataturk Training and Research Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

ilhan bahar

MD,Critical care

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ataturk education research izmir

Izmir, Karabaglar, Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

ilhan bahar, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017/77

Identifier Type: -

Identifier Source: org_study_id